Navigation Links
Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
Date:6/27/2011

proximately 50 sites in the United States.  For additional information on this study, please see www.clinicaltrials.gov (ID NCT01376557).

About LX4211

LX4211 is an orally-delivered small molecule under development as a potential treatment for diabetes.  LX4211 inhibits both sodium-glucose co-transporter type 1 (SGLT1) and sodium-glucose co-transporter type 2 (SGLT2).  SGLT2 is a transporter responsible for most of the glucose reabsorption performed by the kidney.  SGLT1 is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney.  For more information on LX4211, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of clinical trials of LX4211, the mechanism of action of LX4211 and the potential therapeutic and commercial potential of LX4211.  This press release also contains for
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 30, 2015 ... the addition of the "Biomedical Photoacoustic ... offering. This patent landscape focuses ... is a safe, non-invasive, non-ionizing imaging technique. ... a great alternative to traditional medical imaging ...
(Date:7/7/2015)... , July 7, 2015 A power morcellator ... has been settled for an undisclosed amount, Bernstein Liebhard ... filed in March 2014 in the U.S. District Court, ... behalf of a widower whose wife had died in ... a hysterectomy that involved the use of a power ...
(Date:7/7/2015)... California , 7 de julio de 2015 ... médicos de propiedad privada centrada en el desarrollo ... enfermedad neurovascular, ha anunciado hoy que R. ... junta directiva. Kleine cuenta con ... industrias de los dispositivos médicos y la sanidad. ...
Breaking Medicine Technology:Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 2Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 3Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Sequent Medical nombra a Mike Kleine a su junta directiva 2Sequent Medical nombra a Mike Kleine a su junta directiva 3
... VILLAGE, Colo., Jan. 5, 2012 Ampio Pharmaceuticals, Inc. (NASDAQ: ... company that discovers and develops new uses for previously approved ... will hold a Web Cast on Thursday, January 26, 2012 ... to update our shareholders on the company,s progress and a ...
... AMRI ), a global contract services organization, announced ... agreement with BioPontis Alliance LLC. The agreement is aimed ... early-stage research and technologies being discovered and developed in ... services in small molecule discovery, development, and manufacturing in ...
Cached Medicine Technology:Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 2Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 3AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC 2AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC 3
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's headquarters ... facility is a state of the art building, located with easy access to New ... founder, said, "We are pleased to service our clients from such a premier location ...
(Date:7/7/2015)... ... July 07, 2015 , ... Illinois ... board is limited to permit holders. The Medical Cannabis Alliance of Illinois’ (MCAI) ... industry forward and are committed to making sure patients have access to cannabis ...
(Date:7/7/2015)... ... July 07, 2015 , ... SC&H Group, a leading ... aims to give back to the community through company-wide volunteering efforts. , On an ... dedicate the day to assisting those in need throughout Baltimore and Washington D.C. ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, ... Inc. to access its antibody combination therapy (ACT) technology platform. The platform ...
(Date:7/7/2015)... ... ... end of June Pacific Prime Renewals team in Hong Kong announced that they were ... Manager, Danielle Cotton, aims to not only reduce but eventually eliminate the use of paper ... anything between 300 and 600 pieces of paper per month. Not to mention A4 sized ...
Breaking Medicine News(10 mins):Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2
... virus in people, researchers say , FRIDAY, Jan. 22 ... a commonly used drug combination might protect people from ... routes of transmission. , Previous research showed that the ... medication prevented HIV infection through anal sex and intravenously. ...
... important than method, study says , FRIDAY, Jan. 22 (HealthDay News) ... the best time to start potty training may be between the ... 32 months is the ideal window for moving your child out ... more likely to have urge incontinence -- daytime wetting and bed-wetting ...
... reduce harm to mother and baby, researchers say , ... depression, lack of social support and unintended pregnancy are ... of depression in pregnant women, a new study shows. ... and having public insurance coverage, said the University of ...
... known that having a conversation (for example on a cell ... is also true: Driving reduces one,s ability to comprehend and ... of Illinois, appear in the journal Psychonomic Bulletin & ... that driving impairs language skills, said Gary Dell, a psycholinguist ...
... drug fampridine-SR for the treatment of multiple sclerosis. Researchers ... evaluating the effects of the drug in MS for more ... enhance some neurological functions in people with the disease ... by the FDA. "This is a good ...
... team of scientists led by Professor Adrian Krainer, Ph.D., ... in cancer cells that boost the production of an ... The altered metabolic state, called the Warburg effect, promotes ... Discovered eighty years ago by Nobel Prize-winning scientist ...
Cached Medicine News:Health News:Drug Combo Blocks HIV Infection in Mice 2Health News: Potty Training Best Between Ages 2 and 3 2Health News: Potty Training Best Between Ages 2 and 3 3Health News: Potty Training Best Between Ages 2 and 3 4Health News:Driven to distraction: New study shows driving hinders talking 2Health News:Researchers welcome new multiple sclerosis drug 2Health News:Researchers welcome new multiple sclerosis drug 3Health News:CSHL study identifies potential way to reverse cancer cell metabolism and tumor growth 2Health News:CSHL study identifies potential way to reverse cancer cell metabolism and tumor growth 3
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy....
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: